Bowel cancer “melted away” after immunotherapy, then stayed away

Saturday, October 10, 2026

Want headlines delivered to your inbox?
Subscribe to our free daily newsletter.

Search Headlines:

Match Type:BroadStrict



A short course of immunotherapy before surgery may offer remarkably durable protection for some patients with stage two or three bowel cancer. In the NEOPRISM-CRC trial, 32 patients with a specific genetic form of bowel cancer received pembrolizumab for up to nine weeks before surgery instead of the usual post-surgery chemotherapy. After nearly three years of follow-up, none of the patients had experienced a cancer recurrence, including those who still had small traces of disease after treatment. (via Science Daily)

Read the Full Story
This article will expire in 26 days.

In the News...

View All Recent News

Note: News headlines appearing on this site do not reflect the opinion of RxChat.com or its staff.